(UroToday.com) Enzalutamide plus ADT is approved in the US and Europe to treat castration-resistant prostate cancer and was also recently approved for men with metastatic hormone-sensitive prostate cancer (mHSPC) in the US. In ARCHES, enzalutamide plus ADT reduced the risk of the primary endpoint of radiographic progression-free survival events (by 61%), and improved key secondary endpoints versus placebo plus ADT in men with mHSPC.1 Given the progressive nature of prostate cancer, Dr. Azad and colleagues presented results of an exploratory analysis at the GU ASCO 2021 meeting evaluating the efficacy of enzalutamide plus ADT in patients who progressed to M1 HSPC following initial diagnosis (M0) versus patients who presented with de novo mHSPC at diagnosis (M1).